Paper Details

  1. Home
  2. Paper Details

Oral acyclovir suppression of recurrent genital herpes: a double-blind, placebo-controlled, crossover study.

Author: FiddianA P, GabrielsenB O, HalsosA M, HoviT, LassusA, SaloO P, TjøttaE A

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study of 31 men with recurrent genital herpes found that acyclovir (200 mg four times a day) significantly reduced the frequency and duration of outbreaks compared to placebo. Acyclovir completely prevented outbreaks in 77% of patients. Side effects were similar for both treatments. While long-term effects on recurrence rates were not observed, the study suggests that long-term acyclovir treatment may be a viable option for controlling severe forms of genital herpes.
Paper Details　
Original Abstract of the Article :
A randomised, double-blind, placebo-controlled, crossover study was conducted in 31 male patients with a history of frequently recurrent genital herpes who received consecutively 200 mg acyclovir and matching placebo by mouth four times a day for 12 weeks each. During acyclovir therapy recurrences w...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/2578707

データ提供：米国国立医学図書館（NLM）

Recurrent Genital Herpes: A Desert Oasis of Suppressive Therapy

Recurrent genital herpes, a challenging condition that can impact quality of life, can feel as relentless as a desert wind. This study, like a medical oasis offering relief, investigates the effectiveness of oral acyclovir in suppressing recurrent genital herpes. The authors conducted a double-blind, placebo-controlled, crossover study, demonstrating the potential of acyclovir in preventing and reducing the frequency and duration of herpes outbreaks.

Acyclovir: Suppressing Herpes Outbreaks

The study showed that acyclovir significantly reduced the frequency and duration of herpes outbreaks in the majority of patients. This finding suggests that acyclovir can be a valuable tool for managing recurrent genital herpes and improving the quality of life for affected individuals.

Managing Herpes: Balancing Treatment and Prevention

This research highlights the importance of long-term suppressive therapy in managing recurrent genital herpes. While acyclovir can effectively reduce outbreaks, it is crucial to consult with a healthcare professional to determine the optimal treatment approach and manage potential side effects. Understanding the disease and its management strategies can help individuals live with herpes and minimize its impact on their lives.

Dr. Camel's Conclusion

Acyclovir can be effective in suppressing recurrent genital herpes outbreaks and improving quality of life for affected individuals.

Date :
  1. Date Completed 1985-03-21
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

2578707

DOI: Digital Object Identifier

2578707

Related Literature

Article Analysis
・Effective treatment of genital herpes
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.